Lixte Biotechnology Holdings, Inc. financial data

Symbol
LIXT, LIXTW on Nasdaq
Industry
Pharmaceutical Preparations
Location
248 Route 25 A, No. 2, East Setauket, NY
State of incorporation
DE
Fiscal year end
December 31
Former names
SRKP 7 INC (to 12/1/2006)
Latest financial report
10-K - Q4 2024 - Mar 24, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 802 % -40.1%
Return On Equity -190 % -46.2%
Return On Assets -158 % -31.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2.68M shares +19.3%
Common Stock, Shares, Outstanding 2.25M shares 0%
Entity Public Float 5.2M USD +362%
Common Stock, Value, Issued 225 USD 0%
Weighted Average Number of Shares Outstanding, Basic 2.25M shares +17.4%
Weighted Average Number of Shares Outstanding, Diluted 2.25M shares +17.4%

Income Statement

Label TTM Value / Value Unit Change %
Cost of Revenue 356K USD -44.7%
Research and Development Expense 726K USD -19.1%
General and Administrative Expense 2.85M USD -32.1%
Operating Income (Loss) -3.57M USD +29.8%
Net Income (Loss) Attributable to Parent -3.59M USD +29.5%
Earnings Per Share, Basic -1.59 USD/shares +40.2%
Earnings Per Share, Diluted -1.59 USD/shares +40.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.41M USD -16.5%
Assets, Current 1.69M USD -67.7%
Assets 1.15M USD -73.4%
Accounts Payable, Current 45K USD
Liabilities, Current 318K USD +1.41%
Retained Earnings (Accumulated Deficit) -52.1M USD -7.4%
Stockholders' Equity Attributable to Parent 827K USD -79.3%
Liabilities and Equity 1.15M USD -73.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -789K USD +37.9%
Net Cash Provided by (Used in) Financing Activities 6.28K USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 2.25M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -789K USD +37.6%
Interest Paid, Excluding Capitalized Interest, Operating Activities 7.19K USD +86.1%
Deferred Tax Assets, Valuation Allowance 12.6M USD +7.95%
Deferred Tax Assets, Gross 12.6M USD +7.95%
Deferred Tax Assets, Operating Loss Carryforwards 9.52M USD +10.6%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 49.4M USD +0.85%
Share-based Payment Arrangement, Expense 418K USD -45.9%
Interest Expense 16.8K USD +3.62%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%